These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28673587)

  • 21. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies.
    Tanday N; Flatt PR; Irwin N
    Diabet Med; 2021 Dec; 38(12):e14699. PubMed ID: 34562330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bariatric surgery and the gut hormone response.
    Thomas S; Schauer P
    Nutr Clin Pract; 2010 Apr; 25(2):175-82. PubMed ID: 20413698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
    Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
    Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
    Chen S; An FM; Yin L; Liu AR; Yin DK; Yao WB; Gao XD
    Neuroscience; 2014 Jan; 256():137-46. PubMed ID: 24183963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.
    Grams J; Garvey WT
    Curr Obes Rep; 2015 Jun; 4(2):287-302. PubMed ID: 26627223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastric bypass in the pig increases GIP levels and decreases active GLP-1 levels.
    Lindqvist A; Ekelund M; Pierzynowski S; Groop L; Hedenbro J; Wierup N
    Peptides; 2017 Apr; 90():78-82. PubMed ID: 28242256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
    Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bariatric surgery - time to replace with GLP-1?
    Webb DL; Abrahamsson N; Sundbom M; Hellström PM
    Scand J Gastroenterol; 2017; 52(6-7):635-640. PubMed ID: 28276830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?
    Faurschou A; Zachariae C; Skov L; Vilsbøll T; Knop FK
    Med Hypotheses; 2011 Dec; 77(6):1098-101. PubMed ID: 21968278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.
    Holst JJ; Madsbad S
    Surg Obes Relat Dis; 2016 Jul; 12(6):1236-42. PubMed ID: 27313194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1: physiological effects and potential therapeutic applications.
    Aaboe K; Krarup T; Madsbad S; Holst JJ
    Diabetes Obes Metab; 2008 Nov; 10(11):994-1003. PubMed ID: 18435775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery.
    Magro DO; Cazzo E; Kotze PG; Vasques ACJ; Martinez CAR; Chaim EA; Geloneze B; Pareja JC; Coy CSR
    Obes Surg; 2018 Feb; 28(2):378-388. PubMed ID: 28776152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery.
    Holst JJ
    Curr Opin Pharmacol; 2013 Dec; 13(6):983-8. PubMed ID: 24161809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.